Although there are a growing number of well-reported, late-stage clinical trial failures in Alzheimer’s disease, the introduction of a disease-modifying therapy within the next 5 years may be anticipated.

Although there are a growing number of well-reported, late-stage clinical trial failures in Alzheimer’s disease, the introduction of a disease-modifying therapy within the next 5 years may be anticipated.